Literature DB >> 8346196

E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product.

E K Flemington1, S H Speck, W G Kaelin.   

Abstract

Previous studies have shown that the carboxyl-terminal region of E2F-1 (residues 368-437) can support transcriptional activation when linked to the DNA-binding domain of the yeast transcription factor GAL4. This region also contains an 18-residue retinoblastoma (RB)-binding sequence, raising the possibility that RB binding might inhibit the ability of E2F-1 to form protein-protein contacts required for activation. Here we report a further analysis of the E2F-1 activation domain. In addition, we show that overexpression of RB, but not the RB mutant, RBd22, can inhibit GAL4/E2F-1 activity in vivo. Moreover, expression of the simian virus 40 large tumor antigen (T antigen), but not the RB-binding defective T antigen point mutant, K1, can overcome this repression. Three different GAL4/E2F-1 mutants that activate transcription, but fail to bind to RB, are not significantly affected by overexpression of RB. These findings support a model wherein RB suppresses E2F-1-mediated transcriptional activation through direct physical association.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8346196      PMCID: PMC47045          DOI: 10.1073/pnas.90.15.6914

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  The E2F transcription factor is a cellular target for the RB protein.

Authors:  S P Chellappan; S Hiebert; M Mudryj; J M Horowitz; J R Nevins
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

2.  Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product.

Authors:  W G Kaelin; M E Ewen; D M Livingston
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

3.  Rapid site-specific mutagenesis in plasmids.

Authors:  K Foss; W H McClain
Journal:  Gene       Date:  1987       Impact factor: 3.688

4.  SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene.

Authors:  J A DeCaprio; J W Ludlow; J Figge; J Y Shew; C M Huang; W H Lee; E Marsilio; E Paucha; D M Livingston
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

5.  A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding.

Authors:  F J Kaye; R A Kratzke; J L Gerster; J M Horowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway.

Authors:  M Mudryj; S W Hiebert; J R Nevins
Journal:  EMBO J       Date:  1990-07       Impact factor: 11.598

7.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

8.  A new component of the transcription factor DRTF1/E2F.

Authors:  R Girling; J F Partridge; L R Bandara; N Burden; N F Totty; J J Hsuan; N B La Thangue
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962

9.  Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells.

Authors:  H J Huang; J K Yee; J Y Shew; P L Chen; R Bookstein; T Friedmann; E Y Lee; W H Lee
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728

10.  The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations.

Authors:  Q J Hu; N Dyson; E Harlow
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

View more
  111 in total

1.  Apoptosis induced by the nuclear death domain protein p84N5 is inhibited by association with Rb protein.

Authors:  J Doostzadeh-Cizeron; R Evans; S Yin; D W Goodrich
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

2.  Distinct cellular factors regulate the c-myb promoter through its E2F element.

Authors:  M R Campanero; M Armstrong; E Flemington
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

3.  Cumulative effect of phosphorylation of pRB on regulation of E2F activity.

Authors:  V D Brown; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

4.  Induction of cell-cycle regulators in simian immunodeficiency virus encephalitis.

Authors:  K L Jordan-Sciutto; G Wang; M Murphy-Corb; C A Wiley
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

5.  Cytokine-responsive induction of SAF-1 activity is mediated by a mitogen-activated protein kinase signaling pathway.

Authors:  Alpana Ray; Guang-Yao Yu; Bimal K Ray
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

6.  Pattern of expression of p53, its family members, and regulators during early ocular development and in the post-mitotic retina.

Authors:  Linda Vuong; Daniel E Brobst; Anisse Saadi; Ivana Ivanovic; Muayyad R Al-Ubaidi
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-20       Impact factor: 4.799

7.  RB and hbrm cooperate to repress the activation functions of E2F1.

Authors:  D Trouche; C Le Chalony; C Muchardt; M Yaniv; T Kouzarides
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

8.  Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma.

Authors:  R Bremner; D C Du; M J Connolly-Wilson; P Bridge; K F Ahmad; H Mostachfi; D Rushlow; J M Dunn; B L Gallie
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

9.  Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53.

Authors:  C Blattner; A Sparks; D Lane
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

Review 10.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.